Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2023 | Sequential therapy with teclistamab after failure of BCMA-directed CAR-T & the value of bispecifics

Lukas Scheller • 10 Feb 2023
CAR-T Meeting 2023
Multiple Myeloma Antibodies BiTEs CAR-T Teclistamab

Lukas Scheller, MD, University of Würzburg, Würzburg, Germany, highlights the value of bispecific antibodies as a treatment option for patients with multiple myeloma who relapse after BCMA-targeted CAR-T therapy, and summarizes a study which evaluated sequential therapy with teclistamab following failure of BCMA-directed CAR-T. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lukas Scheller

1:53
The detection and management of MNTs following BCMA-directed CAR-T therapy
Lukas Scheller • 16 Feb 2024
0:59
Identifying molecular markers for the prediction of ICAHT in patients receiving CAR T-cell therapy
Lukas Scheller • 16 Feb 2024

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals